← Eichor
Study identifier: NCT06664151 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Condition: Skin Cancer · Cutaneous Squamous Cell Carcinoma (CSCC) · Cutaneous Squamous Cell Cancer  ·  Sponsor: Dana-Farber Cancer Institute

PhaseEARLY_Phase 1
Planned participants25
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine could improve the immune system response against the cancer. The names of the study drug involved in this study is: -Fluzone Influenza vaccine (flu shot)

This description comes directly from the study's public registry record.

Talk to the study team

Karam Khaddour, MD  ·  617-632-6571  ·  karam_khaddour@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting
Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06664151